Macular oedema (retinal vein occlusion) - dexamethasone: review proposal November 2014

Review of NICE Technology Appraisal Guidance No.229; Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion

Proposal to move the existing guidance to the static list

The planned date for review of the above guidance is in 2014.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

There is currently no new evidence available that is likely to lead to a change in the existing recommendations. There are some newly published trials that may provide data for some of the gaps in the evidence identified in TA229, but these are considered to support the recommendations made in the original guidance.

Consequently we propose that TA229 should move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

November 2014


 Appendix A – matrix of stakeholders

Appendix B – proposal paper presented to the Institute’s Guidance Executive

This page was last updated: 20 November 2014